Mpris Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-07-2024
- Paid Up Capital ₹ 0.10 M
as on 01-07-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue -74.38%
(FY 2020)
- Profit -158.54%
(FY 2020)
- Ebitda 73.88%
(FY 2020)
- Net Worth -5.36%
(FY 2020)
- Total Assets -82.70%
(FY 2020)
About Mpris Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Paramjit Sharma and Ajay Sharma serve as directors at the Company.
- CIN/LLPIN
U51909PB2018PTC048462
- Company No.
048462
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Oct 2018
- Date of AGM
29 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Amritsar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Mpris Pharmaceuticals Private Limited offer?
Mpris Pharmaceuticals Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Common Disease Medicines, Injectable Products, Immunization & Vaccination Drugs, Vaccines, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Anti Smoking Drugs, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Mpris Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Paramjit Sharma  | Director | 09-Dec-2019 | Current |
| Ajay Sharma | Director | 01-Oct-2018 | Current |
Financial Performance and Corporate Structure Insights of Mpris Pharmaceuticals.
Mpris Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 74.38% decrease. The company also saw a substantial fall in profitability, with a 158.54% decrease in profit. The company's net worth dipped by a decrease of 5.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mpris Pharmaceuticals?
Unlock access to Mpris Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mpris Pharmaceuticals?
Unlock and access historical data on people associated with Mpris Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mpris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mpris Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
